BioStock: Deep dive into SynAct Pharma’s new strategy

With support from leading rheumatologists, SynAct Pharma is presenting a reshaped strategic plan for resomelagon in rheumatoid arthritis. In addition, they are planning to initiate a phase II trial with resomelagon in influenza patients and prepare the melanocortin agonist TXP-11 for clinical development. BioStock reached out to CEO Torbjørn Bjerke to learn more about the new strategic plan.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/02/deep-dive-into-synact-pharmas-new-strategy/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se